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T umor lysis syndrome (TLS) is a severe complica-tion of cancer treatment that requires immediate 
and urgent intervention.  It is extremely rare in the 
treatment of soft tissue sarcoma (STS).  Presently,  there 
are no reports of TLS in STS of the limbs or trunk as a 
result of the chemotherapeutic agent eribulin.
Herein,  we describe the first case of TLS occurring 
during treatment of STS of the trunk with eribulin,  
along with a review of the available literature.  The 
patient and her family were informed of our intent to 
submit the data from this case for publication,  and gave 
their consent.
Case Presentation
A 78-year-old woman presented at our outpatient 
clinic due to a mass and mild pain in the right buttock 
that had persisted for three months.  She had a history 
of breast cancer,  which had been diagnosed 28 years 
ago,  and a liver abscess one year ago,  but no relapses.  
She had since been treated solely for hypertension and 
hypothyroidism.  Physical examination revealed a hard 
firm lump in the right gluteal area.  Magnetic resonance 
imaging (MRI) showed a large tumor (maximum diam-
eter: 79 mm) spreading under the buttock and within 
the gluteus medius.  This tumor showed an iso signal 
intensity on T1-weighted images (Fig. 1A) and a low-to-
high intensity on T2-weighted images (Fig. 1B-C).  
Since we suspected STS,  a needle biopsy was performed 
to sample the buttock tumor.  Histopathologic examina-
tion revealed spindle-shaped mesenchymal cells show-
ing nuclear swelling and irregularity.  The increased 
chromatin in the nucleus showed dense proliferation 
and a storiform pattern (Fig. 2).  Therefore,  a diagnosis 
of undifferentiated pleomorphic sarcoma (UPS) was 
made.  
Positron-emission tomography (PET)/computed 
tomography (CT) demonstrated 18F-FDG uptake in the 
buttock tumor,  along with uptake in the lymph nodes of 
the right groin and left neck areas (Fig. 3A-C).  A needle 
biopsy was performed of the right groin,  but not the left 
neck; histopathologic examination demonstrated 
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pathological features similar to the tumor in the but-
tock,  confirming the presence of UPS here as well.  
Therefore,  the sarcoma was considered to be stage IV 
according to the 8th edition of the American Joint 
Committee on Cancer (AJCC) staging system [1].
After 6 weeks of 60 Gy curative radiation therapy for 
the tumor of the buttock,  we initiated chemotherapy 
with intravenous eribulin mesylate (Halaven®; Eisai,  
Tokyo) to control the exacerbation of the primary and 
metastatic lesions.  Although this medicine is generally 
used at 1.4 mg/m2 on days 1 and 8 of a 21-day cycle,  we 
administered 0.98 mg/m2 on days 1 and 8 of a 28-day 
cycle due to the patient’s advanced age.  The CT at 
2 months after the initial PET-CT scan,  just before the 
start of eribulin administration,  showed shrinkage of 
the tumor of the right buttock (maximum diameter:  
69 mm),  but revealed new metastatic lesions on the 
right inguinal lymph node and in the liver (Fig. 4A-B).
During the first course of chemotherapy,  the labora-
tory examination on day 15 showed only a slight reduc-
tion in the white blood cell count,  and no other abnor-
malities were found (Table 1).  The white blood cells 
spontaneously recovered,  and the second course was started 
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Fig.  2　 Histopathological findings by a needle biopsy from the 
buttock tumor visualized with hematoxylin and eosin (H&E) staining 
(×400).  Histopathologic examination demonstrated spindle-shaped 
mesenchymal cells showing nuclear swelling and irregularity,  as 
well as increased chromatin in the nucleus with dense proliferation.
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Fig.  4　 Computed tomography (CT) with axial views of abdomen 
(A) and groin (B) at 2 months after the PET-CT scan.  CT showed 
one small metastatic lesion in the liver (A) and swollen inguinal 




Fig.  3　 Positron-emission tomography (PET)/computed 
tomography (CT) with axial views.  PET-CT images showed 
18F-FDG uptake in the buttock tumor (A) as well as in the lymph 





Fig.  1　 Magnetic resonance imaging (MRI) with axial views of 
T1-weighted (A) and T2-weighted (B) images,  and an axial view 
(C) of the buttock.  The tumor revealed an iso signal intensity on 
T1-weighted images and a low-to-high intensity on T2-weighted 
images,  as indicated by the white arrows.
as scheduled,  according to the 28-day cycle.  On day 16 
of the second course,  the patient experienced a loss of 
appetite and fatigue.  After day 16,  she could not eat at 
all,  and she visited our hospital on day 19.  Examination 
revealed that her renal function had deteriorated (blood 
urea nitrogen (BUN): 37.8 mg/dL; creatinine (CRE):  
2.14 mg/dL),  and she had mild hyperkalemia (potassium:  
4.9 mmol/L).  Deterioration of the liver function was 
also confirmed (aspartate aminotransferase (AST):  
124 U/L; alanine aminotransferase (ALT): 195 U/L;  
γ-glutamyl transpeptidase: 572 U/L; and total biliru-
bin: 2.6 mg/dL).  Her vitals were as follows: tempera-
ture of 36.5°C ,  heart rate of 81 beats per minute,  blood 
pressure of 89/35 mmHg,  and 97% oxygen saturation 
on room air.  
She was admitted to the hospital and received volume 
resuscitation (3000 mL/day) and administration of 
furosemide for hypotension and prerenal acute kidney 
injury.  Her blood pressure recovered to 133/70 mmHg 
on the day after admission,  but her renal and liver 
function worsened (BUN: 62.7 mg/dL; CRE: 2.82 mg/dL;  
AST: 500 U/L; and ALT: 430 U/L).  In addition,  
hyperuricemia (uric acid: 12.3 mg/dL),  hypocalcemia 
(calcium: 8.5 mg/dL),  and hyperphosphatemia (inor-
ganic phosphate: 6.0 mg/dL) were observed.  At this 
point,  a CT showed more prominent swelling of the 
liver compared to the CT image taken two months pre-
viously,  and multiple liver and spleen metastases were 
evident (Fig. 5).  We consulted with a nephrologist who 
suggested a diagnosis of TLS due to the presence of 
hyperuricemia,  hyperphosphatemia,  hyperkalemia,  
and renal dysfunction.  We also consulted with a liver 
physician who pointed out the exacerbation of liver 
function due to the destruction of metastatic liver 
lesions using anticancer drugs.  Continuous intrave-
nous hydration and furosemide administration to 
maintain urine output improved the renal function,  
hyperuricemia,  and hyperphosphatemia,  but the find-
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Fig.  5　 Computed tomography (CT) with axial views of the 
abdomen on day 20 of the second cycle.  CT showed more prominent 
swelling of the liver compared to the CT image taken two months 
previously,  and multiple liver metastases and spleen metastases 
(arrow) were observed.
Table 1　 Timeline of laboratory findings during eribulin administration
Parameter Normal range
First cycle Second cycle
Day 1 Day 15 Day 1 Day 15 Day 19 Day 20 Day 21 Day 22
BUN (mg/dL) 8-20 18.8 15.8 15.9 11.0 37.8 62.7 47.4 40.7
CRE (mg/dL) 046-0.79 0.62 0.78 0.57 0.72 2.14 2.82 1.43 1.11
UA (mg/dL) 2.3-7.0 4.5 - - - 9.3 12.3 11.6 10.9
Ca (mg/dL) 8.8-10.1 9.1 9.6 9.2 9.7 9.5 8.5 7.7 7.9
IP (mg/dL) 2.7-4.6 3.1 - - - - 6.0 3.2 2.9
Potassium (mmol/L) 3.6-4.8 3.6 3.5 3.8 3.7 4.9 4.6 3.6 4.0
LDH (U/L) 124-232 192 206 258 486 653 1250 1047 1140
AST (U/L) 13-30 19 25 26 67 124 500 231 242
ALT (U/L) 7-23 17 26 25 138 195 430 366 326
γ-GTP (U/L) 9-32 28 46 57 444 572 474 502 555
T-Bil (mg/dL) 0.4-1.5 0.6 0.8 0.7 - 2.6 2.6 3.5 4.4
WBC (µL) 3300-8600 4700 1900 6200 2800 8500 11000 15500 15600
CRP (mg/dL) 0.00-0.14 0.46 - - 3.66 5.33 5.29 5.25 5.30
BUN,  blood urea nitrogen; CRE,  creatinine; eGFR,  estimated glomerular filtration rate; UA,  uric acid; Ca,  calcium; IP,  inorganic phos-
phate; LDH,  lactate dehydrogenase; AST,  aspartate aminotransferase; ALT,  alanine aminotransferase; γ-GTP,  γ-glutamyl transpepti-
dase; T-Bil,  total bilirubin; WBC,  white blood cell; CRP,  C-reactive protein.
ings of cholestasis continued to worsen.  Hypoxemia 
and consciousness disorder appeared gradually on day 
22.  Given the patient’s poor prognosis overall,  her fam-
ily opted for palliative care with continuous intravenous 
injection of morphine and she passed away on day 23.
Discussion
TLS is an oncological emergency characterized by 
rapid and extensive destruction of tumor cells,  and 
resulting in hyperuricemia,  hyperkalemia,  hyperphos-
phatemia,  and hypocalcemia [2].  TLS presents with 
symptoms such as nausea,  anorexia,  fatigue,  and diar-
rhea,  and in severe cases,  it causes renal dysfunction,  
convulsion,  and arrhythmia,  which may lead to sudden 
death.  Laboratory TLS (LTLS) is diagnosed when the 
laboratory examination values of 2 or more parameters,  
including serum levels of uric acid,  phosphate,  and 
potassium,  are abnormal in patients undergoing che-
motherapy [3].  In addition to LTLS,  clinical TLS 
(CTLS) is diagnosed if there are clinical symptoms such 
as renal dysfunction,  arrhythmia,  and convulsions.  In 
our case,  hyperkalemia improved immediately with 
volume resuscitation; however,  hyperuricemia and 
hyperphosphatemia persisted,  indicating a diagnosis of 
LTLS.  In addition,  renal dysfunction was also present,  
suggesting a diagnosis of CTLS.  According to a previ-
ous report,  the six-month mortality rate in patients 
with TLS and an acute renal injury approaches 66%,  
and TLS is considered a medical emergency in such 
cases [4].
The treatment for TLS is a large volume infusion to 
maintain urine volume,  and the use of diuretics such as 
furosemide,  depending on the urine volume.  In addi-
tion,  uric acid production inhibitors such as allopurinol 
or febuxostat may be used,  although they will have no 
immediate effect.  In our case,  TLS showed a gradual 
improvement with high volume infusion and diuretics.  
However,  hepatic and biliary enzymes continued to rise.  
We believe that the rapid increase in liver and spleen 
metastases due to the weak effect of eribulin,  combined 
with the effects of the partial necrosis of liver metasta-
ses,  resulted in the patient’s death.
TLS most commonly occurs in the initial therapy 
against rapidly proliferating hematological malignan-
cies such as acute lymphoid leukemia and Burkitt’s lym-
phoma.  It is very rarely encountered in the treatment of 
solid tumors [5].  Among the solid tumors that do 
develop TLS,  small cell cancer and hepatocellular carci-
noma are relatively common,  whereas sarcomas are 
distinctly uncommon.  The risk factors for TLS devel-
opment in solid tumors are as follows: large tumor 
burden; extensive metastases; high tumor cell prolifer-
ation rate; high sensitivity to anticancer therapy; and 
increased lactate dehydrogenase (LDH) levels [6 , 7].  In 
the present case,  some of these risk factors,  such as 
high proliferative ability due to rapid progression,  mul-
tiple metastases,  and a high level of LDH,  may have 
affected the onset of TLS.
Only 10 cases of TLS have been reported in sarcoma 
(Table 2) [6-14].  Patients with a solid tumor usually 
develop TLS after intensive chemotherapy,  which is 
known as treatment-induced TLS,  but TLS can some-
times appear before the treatment,  which is referred to 
as spontaneous TLS,  especially in cases of bulky tumors 
with wide necrotic areas [13 , 14].  In our present case,  
because TLS occurred after eribulin administration,  we 
considered that it was treatment-induced.  However,  
the possibility of spontaneous TLS cannot be ruled out,  
since eribulin was not effective.  In the past,  7 in 10 
cases of sarcoma that developed TLS were treat-
ment-induced [6-12].  In most of these cases,  the pri-
mary tumor was located in the abdomen,  including the 
retroperitoneal cavity,  and most patients were at high 
risk for TLS because they had multiple metastases in the 
abdominal cavity,  lymph nodes,  and liver,  and large 
tumor size [6-10 , 12].  On the other hand,  only 1 of 
these cases was suspected of having STS [11].  This case 
was an alveolar rhabdomyosarcoma,  which is a high-
grade sarcoma,  and the risk of TLS was considered high 
because the cancer had spread widely to the bone mar-
row and lymph nodes.  In our case,  multiple lymph 
node metastases and liver metastases occurred.  In gen-
eral,  metastasis of STS occurs most often in the lung,  
and only rarely in the lymph nodes and liver [15-21].  
This is considered to be one of the reasons for the rarity 
of reports of TLS in STS.
Eribulin is a structurally modified analog of hali-
chondrin B,  originally isolated from the marine sponge 
Halichondria okadai,  and it works as a microtubule 
inhibitor.  It exerts its antimitotic effects by inhibiting 
the formation of mitotic spindles,  arresting the cell 
cycle at the G2/M phase [22].  It may be used for the 
treatment of advanced/metastatic breast cancer or cer-
tain metastatic/unresectable sarcomas.  Hematological 
toxicity,  including neutropenia and leukopenia,  is a 
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frequent side effect that requires caution.  In addition,  
side-effects such as liver dysfunction,  gastrointestinal 
manifestations,  and peripheral neuropathy have been 
reported [23].  Ours is only the second case of eribu-
lin-induced TLS,  and the first case of eribulin-induced 
TLS during treatment of STS of the limbs or trunk.  The 
previous report of TLS caused by eribulin was a case of 
leiomyosarcoma of the uterus with lymph node and 
liver metastases [12]; similar to our present case,  that 
patient also developed distant metastases.  Since eribu-
lin is metabolized in the liver,  there is a risk of liver 
damage.  Thus,  it cannot be ruled out that our patient’s 
existing liver metastases may have affected the break-
down of eribulin,  resulting in dysfunction.  Although 
eribulin was used at a reduced dose in our case,  older 
age may have also affected the onset of TLS.  When 
eribulin is used in patients with STS,  caution is neces-
sary,  particularly in elderly patients with multiple 
metastases,  including those in the liver and lymph 
nodes.
In conclusion,  we have presented the first case of 
TLS from treatment with eribulin for STS of the trunk.  
Although TLS is very rare in STS,  caution should be 
exercised when using eribulin in older people with mul-
tiple metastases.
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